As patients with hormone-abnormal PA usually develop insulin resistance and glucose abnormalities [23], activated insulin signaling in NFPAs might antagonize metabolic disorders, thus preventing excessive hormone secretion. This evidence concerns the gene INS and Other metabolic disease.